Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Tempest Therapeutics Inc (TPST)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.46-1.13%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for TPST yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Complete acquisition and integration | A primary condition in Tempest Therapeutics Inc's published investment case. The stated target is Complete integration by end of 2026. | Improving | integration not completed by FY26 | Qualitative progress: CAR-T integration advancing via Senlang option & Factor MSA Senlang CAR-T option and Factor MSA signed; $2.5M raised; board transitions managed. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-stage growth, not an established earnings compounder. The thesis is in a watch state: recent financial performance is weak, management is rated volatile, and evidence of progress is mixed.
The evidence snapshot provides no valuation measure or direct account of market expectations, so whether TPST is cheap, fair, or expensive versus peers cannot be assessed. The recent share-price reaction is described as down, but that alone does not show what expectations are already reflected.
Near term, the risk of another earnings miss is elevated, and the company reported an operating loss in both supplied quarters. For the multi-year thesis, TPST-2003 has positive interim trial findings and manufacturing preparation, but the evidence does not establish that its planned registrational study has begun; TPST-4003 and the in vivo CAR-T platform have limited documented delivery.
The thesis depends on clinical and operational progress, including movement of TPST-2003 toward a registrational study, alongside meaningful partnership development. Near-term pressure could increase if guidance is cut or economic data weakens, while stronger results and guidance from sector bellwethers could support broader Healthcare momentum.
Over the next 1 to 3 years, TPST's thesis remains uncertain and execution-dependent, with limited financial evidence of progress and material financing context given the reported cash balance. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Despite losses, recent EPS estimates improved from -2.76 to -1.34 for 2026. |
| Broken |
| EPS remains below -1.34 in FY26 or worsens in FY27 |
Diluted EPS: $-0.34 per share FY2026-Q2; GAAP. Published target: EPS improves to better than -1.0 by FY27. Annual target cannot be compared with a quarterly or TTM observation. Aug 13, 2026-0.34 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Manage executive transitions | Executive transitions are underway to stabilize leadership. | Under Pressure | Continued high turnover or key executive vacancies beyond FY26 | 3 board resignations (May) vs 0 vacancies target May 2026: 3 board resignations. Oct 2026: CFO replaced, new directors appointed to fill vacancies. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Address Nasdaq compliance issues | Management targets resolving Nasdaq compliance issues to maintain market listing. | Improving | Nasdaq delisting or failure to resolve compliance by Q4 2026 | Qualitative: Board vacancy filled to restore compliance New director appointed to fill vacancy and restore Nasdaq compliance; no delisting notice or failure to resolve reported. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.21 → $-0.90 · observed estimates
$0.06B → $0.06B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-07-25 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-07-26 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-07-27 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-07-28 | $-1.21 | $0 | 1 / 1 |
| 2026-07-29 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-07-30 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-07-31 | $-1.21 | $0 | 1 / 1 |
| 2026-08-01 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-08-02 | $-1.21 | $0 | 1 / 1 |
| 2026-08-03 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-08-04 | $-1.21 | $0 | 1 / 1 |
| 2026-08-05 | $-1.21 | $0 | 1 / 1 |
| 2026-08-06 | $-1.21 | $0 | 1 / 1 |
| 2026-08-08 | $-1.21 | $0 | 1 / 1 |
| 2026-08-09 | $-1.21 | $0 | 1 / 1 |
| 2026-08-10 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-08-12 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-08-13 | $-1.21 | $0 | 1 / 1 |
| 2026-08-14 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-08-15 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-08-16 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-08-17 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-08-18 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-08-19 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-08-20 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-08-21 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-08-22 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-08-23 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-08-24 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-08-25 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-08-26 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-08-27 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-08-28 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-08-29 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-08-30 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-08-31 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-09-01 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-09-02 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-09-03 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-09-04 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-09-05 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-09-06 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-09-07 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-09-08 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-09-09 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-09-10 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-09-11 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-09-12 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-09-13 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-09-14 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-09-15 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-09-16 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-09-17 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-09-18 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-09-19 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-09-20 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-09-21 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-09-22 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-09-23 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-09-24 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-09-25 | $-1.21 | $57,817,500 | 1 / 1 |
| 2026-09-26 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-09-27 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-09-28 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-09-29 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-09-30 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-01 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-02 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-03 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-04 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-05 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-06 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-07 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-08 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-09 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-10 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-11 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-12 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-13 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-14 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-15 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-16 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-17 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-18 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-19 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-20 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-21 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-22 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-23 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-24 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-25 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-26 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-27 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-28 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-29 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-30 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-10-31 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-11-01 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-11-02 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-11-03 | $-0.90 | $57,817,500 | 1 / 1 |
| 2026-11-04 | $-0.90 | $57,817,500 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.